A dose comparison, multi-center, randomized clinical trial to compare the safety and efficacy of LUMAKRAS™ at 960 mg once daily versus a lower daily dose of the drug.
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Sotorasib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2023 According to an Amgen media release, In November, data comparing sotorasib 960 mg versus 240 mg in adults with pretreated KRAS G12C-mutated advanced NSCLC will be presented at a European Society for Medical Oncology (ESMO) Virtual Plenary session.
- 05 May 2021 New trial record
- 28 Apr 2021 anticipates the results from the study in late 2022 and does not expect any impact on the timelines of the ongoing priority review of LUMAKRAS.